Myriad Genetics Inc. (MYGN) Financial Statements (2025 and earlier)

Company Profile

Business Address 322 NORTH 2200 WEST
SALT LAKE CITY, UT 84116
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2835 - In Vitro and In Vivo Diagnostic Substances (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2024
Q3
6/30/2024
Q2
3/31/2024
Q1
12/31/2023
Q4
9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments97,300104,300140,90086,300121,60078,700
Cash and cash equivalents92,40096,900132,10076,000102,80053,600
Short-term investments 4,9007,4008,80010,30018,80025,100
Restricted cash and investments   1,200   
Receivables117,800118,100114,300115,200111,700119,100
Inventory, net of allowances, customer advances and progress billings26,10024,60022,00025,10022,50021,800
Inventory26,10024,60022,00025,10022,50021,800
Prepaid expense18,40018,40017,00017,50017,70017,600
Disposal group, including discontinued operation 10,400     
Other undisclosed current assets21,60024,90018,20021,30020,80024,400
Total current assets:291,600290,300313,600265,400294,300261,600
Noncurrent Assets
Operating lease, right-of-use asset56,50058,90061,600104,000106,600107,000
Property, plant and equipment116,300118,500119,000120,700112,00096,300
Long-term investments and receivables     6,20030,400
Long-term investments     6,20030,400
Intangible assets, net (including goodwill)605,800627,900636,900643,200646,000656,500
Goodwill286,300287,000287,400286,600287,200287,100
Intangible assets, net (excluding goodwill)319,500340,900349,500356,600358,800369,400
Other noncurrent assets14,90014,90015,40015,80022,10017,500
Total noncurrent assets:793,500820,200832,900883,700892,900907,700
TOTAL ASSETS:1,085,1001,110,5001,146,5001,149,1001,187,2001,169,300
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities131,600132,300139,700191,500204,100128,200
Accounts payable33,30033,10025,80033,90039,80036,500
Accrued liabilities98,30099,200113,900157,600164,30091,700
Deferred revenue   500   
Disposal group, including discontinued operation 4,000     
Other undisclosed current liabilities13,30013,80015,70017,80017,00015,100
Total current liabilities:148,900146,100155,900209,300221,100143,300
Noncurrent Liabilities
Long-term debt and lease obligation38,80038,70038,50038,50038,400 
Long-term debt, excluding current maturities38,80038,70038,50038,50038,400 
Liabilities, other than long-term debt125,800134,900138,700188,300163,500162,100
Deferred income tax liabilities    2,7003,7004,100
Other liabilities34,60040,60041,30040,50011,40011,500
Operating lease, liability91,20094,30097,400145,100148,400146,500
Other undisclosed noncurrent liabilities31,10030,80030,20029,60029,00028,700
Total noncurrent liabilities:195,700204,400207,400256,400230,900190,800
Total liabilities:344,600350,500363,300465,700452,000334,100
Equity
Equity, attributable to parent740,500760,000783,200683,400735,200835,200
Common stock900900900800800800
Additional paid in capital1,435,8001,418,8001,415,5001,286,2001,276,8001,262,700
Accumulated other comprehensive loss(4,000)(4,200)(3,700)(5,300)(5,400)(7,400)
Accumulated deficit(692,200)(655,500)(629,500)(598,300)(537,000)(420,900)
Total equity:740,500760,000783,200683,400735,200835,200
TOTAL LIABILITIES AND EQUITY:1,085,1001,110,5001,146,5001,149,1001,187,2001,169,300

Income Statement (P&L) ($ in thousands)

9/30/2024
Q3
6/30/2024
Q2
3/31/2024
Q1
12/31/2023
Q4
9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
Revenues211,500202,200196,600191,900183,500181,200
Cost of revenue(64,400)(64,600)8,000(57,600)(57,800)(59,200)
Cost of goods and services sold(64,400)(64,600) (57,600)(57,800)(59,200)
Gross profit:147,100137,600204,600134,300125,700122,000
Operating expenses(183,600)(165,500)(236,000)(194,400)(239,400)(174,200)
Operating loss:(36,500)(27,900)(31,400)(60,100)(113,700)(52,200)
Nonoperating income (expense)(700)2,000(900)(1,100)(2,400)(400)
Investment income, nonoperating400600700600500700
Other nonoperating income (expense)(300)1,900(700)(700)(2,400)(600)
Interest and debt expense(800)(500)(900)(1,000)(500)(500)
Loss from continuing operations before equity method investments, income taxes:(38,000)(26,400)(33,200)(62,200)(116,600)(53,100)
Other undisclosed income from continuing operations before income taxes8005009001,000500500
Loss from continuing operations before income taxes:(37,200)(25,900)(32,300)(61,200)(116,100)(52,600)
Income tax expense (benefit)500(100)1,100(100) (2,100)
Net loss available to common stockholders, diluted:(36,700)(26,000)(31,200)(61,300)(116,100)(54,700)

Comprehensive Income ($ in thousands)

9/30/2024
Q3
6/30/2024
Q2
3/31/2024
Q1
12/31/2023
Q4
9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
Net loss:(36,700)(26,000)(31,200)(61,300)(116,100)(54,700)
Comprehensive loss:(36,700)(26,000)(31,200)(61,300)(116,100)(54,700)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent200(500)1002002,9001,500
Comprehensive loss, net of tax, attributable to parent:(36,500)(26,500)(31,100)(61,100)(113,200)(53,200)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: